Throat cancer: One third of people diagnosed with oropharyngeal cancer are infected with HPV

A new study suggests that one third of people diagnosed with throat cancer are infected with a form of the HPV virus.

HPV (human papillomavirus) is the major cause of cervical cancer.

Actor Michael Douglas is reported to have spoken about the link after his own diagnosis with throat cancer.

Experts said this study in the Journal of Clinical Oncology, which quantifies the link, showed “striking” results.

There are more than 100 types of HPV. Most people will be infected with HPV at some point, but in most the immune system will offer protection.

A new study suggests that one third of people diagnosed with throat cancer are infected with a form of the HPV virus

There are two HPV strains which are most likely to cause cancer – HPV-16 and HPV-18.

HPV-16 is thought to be responsible for around 60% of cervical cancers, 80% of cancers in the anus and 60% of oral cancers.

This study looked at HPV’s link with cancer of the back of the throat – oropharyngeal cancer.

It looked at blood test results collected from people who took part in a huge prospective study into lifestyle and cancer, who were all healthy at the start.

Everyone gives a blood sample when they join the study, and in this case the researchers were able to check for the presence of antibodies to one of HPV’s key proteins – E6.

E6 knocks out part of cells’ protection system, which should prevent cancer developing.

Having the antibodies means HPV has already overcome that defense and caused cancerous changes in cells.

The researchers compared blood test results – some more than 10 years old – for 135 people who went on to develop throat cancer and for 1,599 cancer-free people.

The University of Oxford team found 35% of those with throat cancer had the antibodies, compared with fewer than 1% of those who were cancer-free.

However, these patients were more likely to survive throat cancer than people whose disease had other causes, such as alcohol or tobacco use.

The study found 84% of people with the antibodies were still alive five years after diagnosis, compared with 58% of those without.